Second-Line Treatment of NSCLC—The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms

In contrast to the established role of epidermal growth factor receptor (EGFR) inhibitors for the first-line treatment of patients with non-small cell lung cancer (NSCLC) harboring activating EGFR mutations, the role of EGFR blockade and of EGFR molecular testing in the second-line treatment remains...

Descripción completa

Detalles Bibliográficos
Autor principal: Köhler, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303897/
https://www.ncbi.nlm.nih.gov/pubmed/28243590
http://dx.doi.org/10.3389/fmed.2017.00009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303897/
https://www.ncbi.nlm.nih.gov/pubmed/28243590
http://dx.doi.org/10.3389/fmed.2017.00009

Ejemplares similares